Yazar "Firat, Sedat Tarik" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The impact of systemic inflammatory markers on survival in metastatic gastric cancer patients receiving first-line chemotherapy
    (2019) Bozkurt, Oktay; Firat, Sedat Tarik; Dogan, Ender; Cosar, Ramazan; Inanc, Mevlude; Ozkan, Metin
    ABSTRACT Aim: The prognostic impact of elevated systemic inflammatory tools, including the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR), remains moot in cancer patients. This research was performed to explore the predictive worth of these markers for prognoses in metastatic gastric cancer (mGC) patients receiving chemotherapy.Material and Methods: We retrospectively appraised 158 patients diagnosed with mGC between February 2009 and November 2017. According to threshold values that were identified by receiver operating characteristic (ROC) curve analysis, the NLR and PLR were each divided into two groups: ≤ 2.11 and >2.11, ≤ 158.8, and >158.8, respectively. The Cox proportional hazards model was applied to uncover the probable predictors of progression-free survival (PFS) and overall survival (OS).Results: According to univariate analysis, poor performance status, high NLR, high PLR, and anemia were significantly correlated with inferior OS receiving first-line palliative chemotherapy. High NLR, high PLR, and anemia were significantly correlated with poor PFS. In the multiple analysis, an elevated NLR was identified to be an independent predictor of inferior OS (OR: 2.70, 95% CI: 1.75-4.16, p0.001) and PFS (OR: 1.47, 95% CI: 1.00-2.17, p=0.047). Additionally, anemia was independent prognostic factors for the OS (OR: 0.69, 95% CI: 0.47-0.99, p=0.046).Conclusion: Findings of this research revealed that NLR was an independent prognostic tool of PFS and OS in mGC patients undergoing first-line chemotherapy.Keywords: Metastatic gastric cancer; neutrophil to lymphocyte ratio; platelet-to-lymphocyte ratio; prognosis.
  • Küçük Resim
    Öğe
    Risk factors for 30-day mortality in patients with cancer and COVID-19 in Turkey: A single center retrospective study
    (2022) Mutlu, Emel; Firat, Sedat Tarik; Inanc, Mevlude; Bozkurt, Oktay; Cosar, Ramazan; Ozkan, Metin
    Aim: We aimed to investigate the factors affecting mortality in cancer patients with COVID-19. Materials and Methods: 120 cancer patients followed-up in Erciyes University Medical Oncology Department were included in the study. Patients with a diagnosed cancer over the age of 18 years and diagnosis of COVID-19 between April 1 and December 1 2020 were participated in the study. The relationship between clinical, demographic, laboratory values and 30-day mortality were evaluated using the Chi-square and Fisher's exact test. Risk factors for mortality were identified by univariable and multivariable logistic regression models. Results: 120 cancer patients were accepted in the study and 30 (25%) had died within 30 days after COVID-19 positivity. Hospitalization rate of cancer patients with COVID-19 was 67.5% and 23 (19.2%) of patients were admitted to intensive care unit (ICU). 34.6% of hospitalized patients and 95.7% of those admitted in the ICU died within 30 days. In multivariable logistic regression analysis, it was concluded that the presence of lymphopenia (OR 2.2, 95% CI 1.54-13.6, p = 0.04), high neutrophil-lymphocyte ratio (NLR) (OR 3.1, 95% CI 1.21-9.8, p = 0.02), dyspnea (OR 2.5 95% CI 0.32-11.2, p = 0.04), lung cancer diagnoses (OR 3.3 95% CI 1.54-9.7, p = 0.03), male gender (OR 2.17 95% CI 1.1-7.3, p = 0.03) ) were determined that increased 30-day mortality. Conclusion: High incidence of cancer and the risk of immunosuppression in these patients increased the importance of COVID-19. Cancer patients with COVID-19 need to be treated more carefully because they are vulnerable to infection and can be mortal.